Boston Harbor skyline
Biotech

How Boston biotechs cope with shallower pool of seed funding

With the average seed round dropping 40% in the first half of the year, CEOs and investors told Fierce where they think the industry is heading.
Will Maddox Oct 16, 2026 7:00am
iRegene Therapeuticss NouvSight001 Cleared for Clinical Trials in the US and China for Retinitis Pigmentosa

iRegene Therapeutics’s NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa

Brought to you by iRegene Therapeutics
China flag against blue sky

China looks to ban foreign acquisitions of key biotech platforms

Oct 16, 2026 10:38am
Estuary river tributary

Estuary emerges with $103M for kidney disease gene therapies

Oct 16, 2026 6:30am
Stock market IPO share price

City scores $200M IPO as Frazier takes biotech SPAC to Nasdaq

Oct 16, 2026 2:47am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Bausch + Lomb CEO heads for exit once more—Chutes & Ladders

Oct 16, 2026 8:30am
More News

Fierce Biotech Fundraising Tracker '26: Estuary, OMass & more

Oct 16, 2026 6:30am

OrbiMed’s largest-ever Asian fund contributes to $3B war chest

Oct 15, 2026 9:18am

AstraZeneca, insitro ink $1.5B AI-enabled target discovery deal

Oct 15, 2026 6:00am

Rebranded Galapagos finally finds buyer for cell therapies

Oct 15, 2026 4:09am